3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
10
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Liposarcoma
1
Female Patients Under the Age of 65 Who Will Undergo Breast Cancer Surgery
1
Epilepsy
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
3
spartalizumab
2
sargramostim
2
trametinib
1
tislelizumab
1
nazartinib
1
fludarabine phosphate
1
enzalutamide
1
canakinumab
1
bemarituzumab
1
Specimen Handling
1
Midazolam
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Interleukin-13
1
IFL protocol
1
Fulvestrant
1
Fluorodeoxyglucose F18
1
Cyclophosphamide
1
Cetuximab
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Midazolam
×
Breast
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled